5th Edition of Cardiology world Conference | September 05-07, 2024 | Hybrid Event

Welcome! I am thrilled to share the latest advancements in heart failure treatment with you, particularly focusing on sotagliflozin, a groundbreaking therapy offering new hope to patients.

Sotagliflozin is a dual SGLT1 and SGLT2 inhibitor in recent studies have unveiled its significant benefits in treating heart failure, even in patients without diabetes. This dual inhibition mechanism not only lowers blood glucose levels but also has profound effects on heart health.

Clinical trials have demonstrated that sotagliflozin significantly reduces the risk of cardiovascular death and hospitalization due to heart failure. Its ability to promote natriuresis (sodium excretion) and reduce cardiac workload helps alleviate symptoms and improve the quality of life for heart failure patients. Additionally, sotagliflozin's impact on reducing body weight and blood pressure further supports its role in comprehensive heart failure management.

One of the most exciting aspects of sotagliflozin is its effectiveness across a broad spectrum of heart failure patients, including those with preserved and reduced ejection fractions. This versatility makes it a valuable addition to the current treatment options, offering a new therapeutic avenue for patients who may not have responded well to existing therapies.

As we continue to explore and understand the full potential of sotagliflozin, it represents a significant step forward in our fight against heart failure. I am confident that this innovative treatment will play a crucial role in improving patient outcomes and enhancing the quality of care.

Thank you for your attention, and I look forward to the fruitful discussions ahead.

5th Edition of Cardiology World Conference | Hybrid Event

Advanced heart failure is a deadly disease and survival is worse than for breast or prostate cancer. There is a high risk of sudden death. There frequent hospital readmissions and the quality of life is very poor

Heart transplantation at this stage is regarded as the standard in selected patients, however, only a small number of patients have access to donor organs. Early and long-term complications are significant.

For quite some time implantable durable left ventricular assist devices have become a realistic alternative. They are available at any given time. There is no early failure of the transplanted heart and no toxic side effects from chronic immunosuppression. The early and long-term outcomes have become excellent. Innovation of technology will lead to further improvement and will simplify the management and will allow a normal quality of life.

5th Edition of Cardiology World Conference | Cardio 2024

As the Conference Organizing Committee Member and Keynote Speaker, I am very honored to write this welcome message.

The current conference, 5th Edition of Cardiology World Conference, aims to address the global challenge posed by cardiovascular disease, a leading cause of approximately 15 million annual fatalities worldwide.

Clearly, the upcoming Cardiology World Conference is an annual collaboration that brings together leading researchers, scientists, clinicians, and industry professionals from cardiovascular health and disease fields around the world. The conference will include outstanding keynote sessions, plenary lectures, invited speeches, research presentations, technical demonstrations, and panel discussions around the world.

All the planned latest cutting-edge presentations and demonstrations will highlight the recent past, current, and future cardiovascular research, explore innovative technologies in cardiovascular disease treatment, and shed light on advancements in managing cardiovascular diseases. Furthermore, all participants including prominent researchers, cardiologists, cardio-thoracic surgeons, healthcare professionals, professors, scientists, students, nurses, and business professionals can gain valuable perspectives from diverse corners of the globe, accelerate breakthroughs in science, trials, and innovations within the realm of cardiology, share their latest research findings, and energize innovative developments and discoveries to unveil breakthroughs and shape future various objectives.

I am very excited to look forward to meeting with you at this upcoming fantastic conference.

5th Edition of Cardiology World Conference | Madrid, Spain

I am most pleased to invite you to participate in a well-thought out and well planned cardiology Conference “Cardio 2024” to be held in Madrid, Spain during September 5-7, 2024. The Scientific program for this meeting will contain several sessions and invited lectures by some high profile speakers. The conference will focus on discussions and new developments in the area of pathogenesis and therapeutics of heart failure, myocardial infarction, arrhythmias and ischemic heart disease. All residents and fellows as well as academic cardiologists and scientific investigators in the field of cardiovascular medicine will have excellent opportunity of learning new information and improve their skills for the treatment of cardiovascular disease.

5th Edition of Cardiology World Conference

Dear colleagues and participants, as a scientific committee member and keynote speaker, it gives me great honor and pleasure to write this welcome note. Cardiovascular disease remains the main cause of morbidity and mortality globally. With the advancement of genetic and cell biology in life sciences as well as new technologies, numerous cutting-edge research findings are made to improve our understanding of the underlying molecular mechanisms, treatment, and prevention of cardiovascular disease. More excitingly, interactions among vast international researchers are likely to further spark novel ideas, remind potential issues, and find solutions. The Cardiology World Conference, Cardio 2024, that provides a major platform for keynote, plenary talks and poster presentations with both academic and industrial scientific sessions, offers exactly such an outstanding opportunity. I enthusiastically look forward to interacting with you at this exciting international conference for exchanges of ideas and knowledge to advance cardiovascular research and care.

Cardio 2024 | September 05-07, 2024

Welcome to Cardio 2024!

We're excited to introduce Cardio-HART™, an AI-enabled cardiac diagnostic tool designed for point-of-care use. Although AI promises significant advances, they are typically not practical for immediate point-of-care use. This leaves patients waiting with outdated capabilities and relying on referrals to echocardiography, leading to delayed diagnoses and disease progression.

Cardio-HART™ addresses this by using AI to augment and complement ECG, enhancing its diagnostic capabilities. It identifies heart diseases typically diagnosed by echocardiography in secondary care, reducing diagnosis time for heart failure and valve disease from months to same-day as patient presentation. This enables quicker access to treatment and reduces the burden on secondary care.

Cardio-HART™ is to echocardiography what echocardiography is to cardiac-MRI, providing advanced diagnostic capabilities in a simple ECG-like intervention. It decreases unnecessary echocardiograms and eases emergency department pressures by improving point-of-care detection, lowering costs, improving patient outcomes.

Join us at Cardio 2024 to learn more about this innovation.

5th Edition of Cardiology World Conference | September 05-07, 2024

The beginning of the 21st century has gone down in the history of medicine as a time of globalization and socialization of some chronic diseases. Recently, we also faced a pandemic of a viral infection, which primarily affected patients with cardiovascular diseases in adults. Thus, the comorbidity of cardiovascular diseases and other somatic diseases continues to make a large contribution to the development of complications and mortality among adults in most countries. Therefore, the introduction of innovative technologies along with prevention strategies at different levels are an important part of the fight against cardiovascular diseases. The program of the annual conference on cardiology includes current topics on the diagnosis and treatment of cardiac patients. These results of the reports can be useful for both researchers and practitioners. I invite my colleagues to actively participate in the conference.

3rd Edition of Cardiology World Conference | Online

Dear participants of the World Conference on Cardiology.

Cardiovascular disease continues to lead the way in complications and deaths among adults around the world. In developed countries, the incidence rate has decreased, while in developing countries, these rates are somewhat different. Numerous international studies are being carried out to improve the diagnosis, treatment and, most importantly, the prevention of cardiovascular diseases. As data accumulates, international recommendations are updated. It is safe to say that international treatment standards are applied in all countries. But there is a lot of work to be done to introduce innovative technologies in cardiology.

I believe that scientific and educational conferences with the exchange of opinions of specialists from different countries are positively reflected  in the accumulation of experience in the fight against cardiovascular diseases.

I call on my colleagues to actively participate in the work of the World Conference on Cardiology 2022 and wish you success.

Cardiology World Conference, October 24-25, 2019 | Tokyo, Japan

One of the themes of this conference is that of myocardial ischaemia and infarction. At first glance, this would seem to represent purely a repetition of our previous focus on the traditional theme of a common spectrum of cardiovascular disorders driven by the traditional risk factors of hypertension, smoking, diabetes and poor diet, and emerging mainly in middle-aged men. Our therapeutic discussion 30 years ago would have emphasised coronary revascularization above all. However, much has changed. In Western societies, emergence of coronary atheroma-related disease has generally been delayed, if not prevented, while an emerging epidemic threatens the Third World. We have finally learned the importance of inflammation as a key component of the pathogenesis of atherogenesis and myocardial Welcome Message ischaemia, and are beginning to refine our pharmacotherapy to accommodate the recognition of its potential effectiveness and the emergence of “new” forms of acute heart disease which occur mainly in women. I welcome you to the ischaemia/infarction section of the Conference, and trust that you will find our discussions exciting and providing of a better guide to future treatment.

Cardiology World Conference, October 24-25, 2019 | Tokyo, Japan

Dear conference participants and colleagues, I am glad to welcome you to the international conference on cardiology. Cardiovascular diseases are still the main cause of complications and mortality in adults. Moreover, this global trend is observed in both developed and developing countries of the world. Conducted international clinical studies to identify risk factors, primary and secondary prevention of cardiovascular diseases. Annually, the results of major projects on the effectiveness of drugs and new technologies are published. In the 21st century, digital technologies are increasingly used in cardiology. The international conference will highlight various areas in cardiology, which will help in the practical work of specialists. I wish you fruitful work.

Cardiology World Conference, October 24-25, 2019 | Tokyo, Japan

Dear congress visitors, It gives me great pleasure to write a few welcome notes. The field of cardiovascular biomarker research is entering a new, exciting era with the introduction of the concept of ‘personalized medicine’ in therapeutic treatment guidance. With a variety of new cardiovascular biomarkers, and assertions of their respective independent associations with outcome, it becomes increasingly difficult to select the biomarker with the strongest diagnostic as well as prognostic value. One can expect that the increasing use of cardiovascular biomarkers, accompanying traditional diagnostic and prognostic measures, for specific cardiovascular diseases, will lead to their almost crucial role in clinical decision making. However, the search for an ideal biomarker, or set of biomarkers, requires a systematic and rigorous approach to biomarker studies, more emphasis on Welcome Message prospective studies, and use of external validation cohorts. Accomplishment of the previous will lead to improved quality of diagnostic and, even more important, prognostic biomarker research in the future, and will be required if we want to bring this clinically important research field forward.

Cardiology World Conference, October 24-25, 2019 | Tokyo, Japan

Dear congress participants, it is an honor and pleasure to write a few welcome notes. During the last decade, research in cardiovascular field has dramatically increased leading to a substantial improvement in the treatment and the outcome of patients affected with cardiovascular diseases. The main theme of the “Cardiology World Conference” (CWC 2019) will be the “Advances in Cardiology: Research and Innovations”. Latest breaking trials, innovations and hot topics will be discussed in depth during the event involving different fields and specialties contributing to cardiovascular research. Hence, we strongly believe that CWC 2019 will represent a major platform for promoting and advancing cardiology in its dynamic field. We look forward to welcoming you in Tokyo (Japan), for what promises to be an unforgettable Conference. See you there!